Tough FDA panel review in sight for B+L?
This article was originally published in Clinica
Executive Summary
Bausch + Lomb’s Trulign Toric intraocular lens could face a grilling at an FDA advisory panel meeting today, if the agency’s briefing documents are anything to go by. If given the thumbs up by the panel, the device could become the first toric accommodating IOL to be approved by the FDA – it is intended for lens replacement in cataract patients to restore both accommodation (the ability to focus on near objects) and correction of corneal astigmatism.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.